Asian Currencies Slip as Dollar Rebounds Ahead of Fed Rate Decision 
U.S. Stock Futures Edge Lower as Tech Earnings and Fed Decision Shape Market Sentiment 
Gold Prices Pull Back After Record Highs as January Rally Remains Strong 
CSPC Pharma and AstraZeneca Forge Multibillion-Dollar Partnership to Develop Long-Acting Peptide Drugs 
The Maire - EuroChem Case: Three Lessons for Global Business 
Apple Earnings Beat Expectations as iPhone Sales Surge to Four-Year High 
Indonesia Stocks Face Fragile Sentiment After MSCI Warning and Market Rout 
Sandisk Stock Soars After Blowout Earnings and AI-Driven Outlook 
Apple Forecasts Strong Revenue Growth as iPhone Demand Surges in China and India 
Asian Stocks Waver as Trump Signals Fed Pick, Shutdown Deal and Tech Earnings Stir Markets 
Dollar Struggles as Policy Uncertainty Weighs on Markets Despite Official Support 
South Korea Industry Minister Heads to Washington Amid U.S. Tariff Hike Concerns 
Oil Prices Hit Four-Month High as Geopolitical Risks and Supply Disruptions Intensify 
Trump Threatens 50% Tariff on Canadian Aircraft Amid Escalating U.S.-Canada Trade Dispute 
Pentagon and Anthropic Clash Over AI Safeguards in National Security Use 
Trump Threatens Aircraft Tariffs as U.S.-Canada Jet Certification Dispute Escalates 
Toyota Retains Global Auto Sales Crown in 2025 With Record 11.3 Million Vehicles Sold 
Daewoong’s Nabota was banned by the U.S. International Trade Commission late last year. The agency imposed a 21-month import and sale ban on the South Korean company’s botulinum toxin product brand.
The prohibition resulted from the verdict handed down by the ITC regarding Medytox’s 5-year legal battle against Daewoong Pharmaceutical. Apparently, the commission ruled in favor of the Gangnam-gu-based biopharmaceutical company. The two Korean firms are battling in court over the misappropriation of trade secrets complaints.
ITC revokes ban on Daewoong’s Nabota
This week, the US ITC has lifted the restriction on Daewoong’s botulinum toxin products. This means the firm can now resume the sale and import of its Nabota products that is also known as Jeuveau, in the U.S.
The Korea Herald reported that the latest decision would let Evolus, Daewoong Pharma’s partner based in the United States, to start selling Nabota in the region again. In any case, the ban was lifted after Medytox, Evolus, and AbbVie, Allergan’s parent company, agreed to resolve their dispute in February.
As part of the deal, the three corporations will also dissolve all the remaining cases at the ITC, including the sale of Nabota in the U.S. and other countries where Evolus has licensing rights.
How the companies settled the dispute
Moreover, it was revealed that Evolus agreed to pay Medytox and Allergan $35 million that will be paid in a series of lump sums in the span of two years. The Daewoong partner has to pay royalties to Medytox and Allergan based on Nabota’s net sales for 21 months. After this, Evolus will be paying royalties to Medytox alone.
Allergan is also involved in the case of Daewoong because botulinum toxin is the main component in Botox, a type of treatment for wrinkles. Allergan is the company that sells Botox.
Meanwhile, as per Pulse News, Daewoong Pharmaceutical Co.’s shares have increased on Tuesday, May 4. The numbers have jumped by 5.93 percent to close at ₩134,000 or around $119.37. This figure is expected to increase now that Nabota is being allowed to be sold again in the United States further.
